Clinical Trial Update: Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose [Phase 4]

View source ↗

Summary

Phase 4 study assessing whether the calcium channel blocker amlodipine influences serum FGF-23 levels and other clinical/laboratory parameters in adults with ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus with Proteinuria

Drugs mentioned

• Amlodipine (amlodipine)

Snippet

Sponsor: Gulhane School of Medicine | Conditions: We Searched for the Effects of Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria. | Phase 4 | Status: COMPLETED